(Q36206304)

12 August 2017

Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway (English)

1 reference

12 August 2017

1 reference

Hongbing Chen

1

1 reference

12 August 2017

Yin Sun

2

1 reference

12 August 2017

Chengyu Wu

3

1 reference

12 August 2017

Clara E Magyar

4

1 reference

12 August 2017

Xinmin Li

5

1 reference

12 August 2017

Liang Cheng

6

1 reference

12 August 2017

Jorge L Yao

7

1 reference

12 August 2017

Steven Shen

8

1 reference

12 August 2017

Adeboye O Osunkoya

9

1 reference

12 August 2017

Chaozhao Liang

10

1 reference

12 August 2017

Jiaoti Huang

11

1 reference

12 August 2017

24 May 2012

1 reference

12 August 2017

Endocrine-Related Cancer

1 reference

12 August 2017

19

1 reference

12 August 2017

321-331

1 reference

12 August 2017

3

1 reference

PC3 is a cell line characteristic of prostatic small cell carcinoma.

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Neuroendocrine differentiation in prostate cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NF-kappaB synergy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Chemokine signaling via the CXCR2 receptor reinforces senescence

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

AR, the cell cycle, and prostate cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Immunohistochemical characterization of neuroendocrine cells in prostate cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Small cell carcinoma of the prostate: an immunohistochemical study.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Protein tyrosine phosphatase PTP1B is involved in neuroendocrine differentiation of prostate cancer.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Prostate cancer 2004: insights from national disease registries.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Unusual subtypes of prostate cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Molecular characterization of human prostate carcinoma cell lines

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Prostate carcinoma: defining therapeutic objectives and improving overall outcomes

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Brain metastasis from prostate small cell carcinoma: not to be neglected

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Prostate cancer in a transgenic mouse

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3433057

Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate

22 September 2018

1 reference

12 December 2020

Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer

1 reference

12 December 2020

An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line

1 reference

12 December 2020

Clinical significance of p53 alterations in surgically treated prostate cancers

1 reference

12 December 2020

Function and molecular mechanisms of neuroendocrine cells in prostate cancer

1 reference

12 December 2020

Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth

1 reference

12 December 2020

Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles

1 reference

12 December 2020

Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy

1 reference

12 December 2020

Progression of prostate cancer to neuroendocrine cell tumor

1 reference

12 December 2020

Identifiers

DOI

10.1530/ERC-11-0368

1 reference

12 August 2017

1 reference

12 August 2017

1 reference